Nuclear Medicine

OPTION-12/5 scores show small absolute SDM improvement and wide heterogeneity

This meta-analysis of 174 studies (nearly 20,000 encounters) found baseline observer SDM scores were low: OPTION-12 mean 25.1 and OPTION-5 mean 31.8. Postintervention OPTION scores were higher (OPTION-12 38.4, OPTION-5 47.7), but heterogeneity remained very high. Multivariable analyses found clinical setting predicted OPTION-12 and consultation duration predicted OPTION-5. Clinicians and researchers should interpret modest score changes cautiously and consider contextual measurement limits. 1

Proposal for consensus framework to report protocol and SAP modifications

Authors argue that inconsistent reporting of protocol and statistical analysis plan modifications hampers appraisal of RCT trustworthiness. They propose a Delphi-informed, consensus-based framework to document what changed, when, and why. Standardized change logs would let reviewers and clinicians assess potential bias from postrandomization or data-driven changes. Until adoption, scrutinize trial documents for dispersed change information and question unexplained modifications. 2

One-strength accelerated HDM SCIT as safe and tolerable as standard regimen

In a multicenter RCT of 211 Chinese adolescents and adults, systemic adverse reactions were similar between One-strength (7.4%) and Standard (8.7%) SCIT. Most reactions were local and WAO grade 1–2; no grade ≥3 events occurred. Tolerability ratings favored the One-strength regimen (approximately 84% good/very good vs 70% for standard). Apply to adolescents and adults receiving HDM SCIT in similar clinical settings, noting limited generalizability outside China. 3